We have summarised the available evidence on several key areas of ophthalmic management in pregnant women, including a discussion on complex and potentially controversial topics such as treatment with intravitreal anti-VEGF agents in pregnancy, IOP-lowering medications, and considerations on mode of delivery in pregnant women with chorioretinal disease. This evidence concerns the gene VEGFA and chorioretinitis.